A Study of Bezafibrate in Mitochondrial Myopathy
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02398201|
Recruitment Status : Completed
First Posted : March 25, 2015
Last Update Posted : September 21, 2017
The purpose of this study is to gather preliminary data on whether bezafibrate can improve cellular energy production in mitochondrial disease.
Mitochondrial diseases are rare inherited disorders that arise due to deficient energy production within the cells of the body. Consequently, the typical clinical features arise in organs with high energy requirements. Mitochondrial disorders exhibit highly variable clinical effects, both between individuals and within families. Characteristic symptoms include muscle weakness (myopathy), hearing loss, migraine, epilepsy and stroke like episodes in addition to diabetes and heart problems. Mitochondrial disorders can therefore impact considerably on both quality of life and life expectancy. Despite this, no proven disease modifying treatments are available.
Pre-clinical studies have identified that several existing medications improve mitochondrial function. Of these, bezafibrate has the best supportive data and, because it is already licensed as a treatment for high blood fats, has a well characterised side effect profile.
The investigators will therefore conduct a feasibility study of bezafibrate in people with mitochondrial myopathy. Ten affected participants will be recruited and will receive a titrating course of bezafibrate three times daily for 12 weeks.
|Condition or disease||Intervention/treatment||Phase|
|Mitochondrial Diseases||Drug: Bezafibrate||Phase 2|
Mitochondrial disorders are genetically determined metabolic diseases affecting approximately 1 in 5000 people. Current strategies for treating mitochondrial disorders are limited, and restricted to alleviating symptoms. A recently published Cochrane review did not identify any disease modifying treatments of proven benefit. There is therefore an urgent and currently unmet need for treatments that modify the underlying biochemical deficit and disease trajectory.
Improving deficient oxidative phosphorylation (OXPHOS) pathways through induction of mitochondrial biogenesis is a potential approach to the treatment of mitochondrial disorders. This involves stimulating transcription factors for both nuclear and mitochondrial genomes simultaneously in order to up-regulate respiratory chain (RC) gene expression. This role is fulfilled by peroxisome proliferator activated receptor (PPAR)-γ coactivator-1α (PGC-1α); a pivotal transcriptional co-factor widely considered the master regulator of mitochondrial biogenesis.
PGC-1α interacts with a number of transcription factors. These include α, β/δ and γ isoforms of the peroxisomal proliferator activated receptors (PPARs). This group of ubiquitously expressed nuclear receptors is activated by binding of fatty acids. Subsequently, transcription of genes involved in mitochondrial fatty acid oxidation is induced, thereby enabling cellular metabolic shift from glycolysis. Additionally, PGC-1α co-activates estrogen related receptor alpha (ERRα); nuclear respiratory factors (NRF) 1 and 2 (transcription factors bound to promoter regions of target nuclear genes involved in the respiratory chain); and TFAM (transcription factor A mitochondrial), which modulates mitochondrial DNA transcription and replication.
PGC-1α expression is induced through cold exposure, starvation and exercise. The PPARs, AMP-protein activated kinase (AMPK) and sirtuin 1 (Sirt1) also increase PGC-1α activity and provide a means through which this pathway can be pharmacologically manipulated. Indeed, several compounds have been identified that exert their effect in this way including: bezafibrate and the glitazones (PPAR agonists); metformin and AICAR (AMPK); and resveratrol (Sirt1). Of these, bezafibrate, glitazones and metformin have established relevance in diabetes and hyperlipidaemia. Their mechanism of action also provides a rationale for their use in other metabolic disorders such as obesity and mitochondrial disease.
Indeed,bezafibrate has shown promise as a disease modifying pharmaceutical agent in pre-clinical studies using both cellular and animal models of mitochondrial myopathy.
Cellular models of mitochondrial disease have demonstrated improvements in a variety of measures of mitochondrial function when grown in a bezafibrate enriched medium. This has included a cell line comparable to the specific patient group we propose to review in this feasibility study. Furthermore, a mouse model of mitochondrial myopathy has demonstrated improvement in clinically relevant outcomes including time to disease manifestation and life span.
This phase II, open label, non-randomised feasibility study aims to build on the work obtained in pre-clinical studies and provide proof of principle data in humans affected with the most common form of mitochondrial muscle disease. This study is not designed to provide proof of efficacy. However, should bezafibrate exert a demonstrable molecular effect here, the investigators anticipate the need for larger, randomised trials of bezafibrate in the future. An additional aim of this feasibility study, is therefore obtaining the relevant data to determine how many patients the investigators would need in a larger trial; and what biochemical and clinical measurements the investigators would use to determine drug effect in such a trial.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||6 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Feasibility Study of Bezafibrate in Mitochondrial Myopathy|
|Study Start Date :||September 2015|
|Primary Completion Date :||January 2017|
|Study Completion Date :||March 23, 2017|
Bezafibrate tablets (200-600mg) three times daily for 12 weeks.
Bezafibrate 200mg-600mg three times daily for 12 weeks.
Other Name: Bezalip
- Change in Respiratory Chain Enzyme Activity [ Time Frame: baseline and 12 weeks ]
- Change in citrate synthase [ Time Frame: baseline and 12 weeks ]
- Change in mitochondrial DNA copy number [ Time Frame: baseline and 12 weeks ]
- Change in COX negative fibres [ Time Frame: baseline and 12 weeks ]
- Change in serum Fibroblast Growth Factor-21 concentration [ Time Frame: baseline, 3, 6, 9, 12 weeks ]
- Change in PGC-1alpha concentration [ Time Frame: baseline, 3, 6, 9, 12 weeks ]
- Change in micro-RNA expression pattern [ Time Frame: baseline, 3, 6, 9, 12 weeks ]
- Change in cardiac 31P-MRS [ Time Frame: baseline and 12 weeks ]We will specifically analyse ATP production and muscle phosphocreatine pre and post bezafibrate
- Change in cardiac cine MRI [ Time Frame: baseline and 12 weeks ]We will analyse LV (left ventricular) torsion pre and post bezafibrate
- Change in skeletal muscle 31P-MRS [ Time Frame: baseline and 12 weeks ]We will analyse ATP production, muscle phosphocreatine, t1/2 PCR (phosphocreatine), muscle lipid content and volume.
- Change in IPAQ (international physical activity questionnaire) score [ Time Frame: baseline, 6 and 12 weeks ]
- Change in accelerometry [ Time Frame: baseline, 6 and 12 weeks ]
- Change in Timed Up and Go (TUG) time [ Time Frame: baseline, 6 and 12 weeks ]
- Change in NMDAS (Newcastle Mitochondrial Disease Adult Scale) score [ Time Frame: baseline, 6 and 12 weeks ]
- Change in heteroplasmy level [ Time Frame: baseline and 12 weeks ]measured in blood, urine and muscle
- Change in NMQ (Newcastle Mitochondrial Disease Quality of Life) Score [ Time Frame: baseline, 6 and 12 weeks ]
- Change in Fatigue Impact Scale score [ Time Frame: baseline, 6 and 12 weeks ]
- Number of Adverse Events [ Time Frame: 0,1,2,3,4,5,6,7,8,9,10,11,12,13,14 weeks ]Adverse events will be captured every week with opportunistic capture between visits as required.
- Change in Full Blood Count [ Time Frame: 0,1,2,3,4,5,6,7,8,9,10,11,12 weeks ]White cell count; Haemoglobin; Platelet count
- Change in Urea & Electrolytes [ Time Frame: 0,1,2,3,4,5,6,7,8,9,10,11,12 weeks ]Sodium; Potassium; Urea; Creatinine;
- Change in Liver Function Tests [ Time Frame: 0,1,2,3,4,5,6,7,8,9,10,11,12 weeks ]Alkaline Phosphatase, Alanine Transferase, Aspartate Aminotransferase, Gamma Glutamyl Transferase
- Change in Creatine Kinase [ Time Frame: 0,1,2,3,4,5,6,7,8,9,10,11,12 weeks ]
- Change in Prothrombin Time [ Time Frame: 0,1,2,3,4,5,6,7,8,9,10,11,12 weeks ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02398201
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02398201
|Clinical Research Facility, Royal Victoria Infirmary|
|Newcastle upon Tyne, Tyne and Wear, United Kingdom, NE1 4LP|
|Principal Investigator:||Patrick F Chinnery, MBBS, PhD||Newcastle Univeristy|